Amgen Invests Additional $300 Million in Puerto Rico Biomanufacturing Expansion

San Juan: Amgen announced an additional $300 million investment in its manufacturing operations in Juncos, Puerto Rico, expanding the company’s efforts to strengthen its U.S. biomanufacturing network and increase production capacity.

The new investment will support advanced manufacturing technologies and infrastructure upgrades at the Puerto Rico facility, which plays a major role in the company’s global operations.

Amgen Chairman and Chief Executive Officer Robert Bradway said the investment is intended to help ensure patients have access to critical medicines while strengthening domestic supply chains and supporting American jobs.

The latest funding follows several large U.S. investments announced by Amgen over the past year, bringing the company’s total recently announced domestic manufacturing and innovation commitments to nearly $2 billion.

Puerto Rico Operations Continue to Expand

The new $300 million commitment builds on a previously announced $650 million investment in Amgen’s Puerto Rico manufacturing operations in September 2025.

Combined, the investments represent nearly $1 billion directed toward the company’s operations in Juncos.

Puerto Rico Secretary of Economic Development and Commerce Sebastián Negrón Reichard said the investment demonstrates growing confidence in Puerto Rico’s pharmaceutical manufacturing sector and workforce.

He stated that the expansion reinforces Puerto Rico’s role as a major center for American biomanufacturing and life-saving medicine production.

Broader U.S. Manufacturing Push

Amgen has significantly expanded its U.S. investments in recent years. In addition to Puerto Rico, the company announced a $900 million investment in Ohio last year and another $600 million investment in a science and innovation center in California.

Since 2024, Amgen has also invested more than $1.5 billion in North Carolina operations.

The company says it has committed more than $40 billion toward manufacturing and research and development projects across the United States since 2017.

Biopharmaceutical Industry Expands U.S. Presence

Amgen is among several major pharmaceutical companies increasing manufacturing investments in the United States.

Novartis recently announced a $23 billion expansion strategy for its U.S. operations, including a new facility in North Carolina designed to strengthen domestic production capabilities.

Meanwhile, biopharmaceutical company UCB is developing a new biologics manufacturing facility in Georgia that will incorporate AI, robotics, automation, and digital-first production systems.

Industry analysts say these investments reflect growing efforts by pharmaceutical companies to modernize production systems, improve supply chain resilience, and expand domestic medicine manufacturing capacity.